 |
5 Products |  |
33 Diseases | | 5 Products |
|
1369 Trials |  |
5508 News |  |
| «12...3031323334353637383940...4748» |
- | Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Trial initiation date, Metastases: Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer (clinicaltrials.gov) - Mar 9, 2021
P2, N=40, Recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
Not yet recruiting --> Recruiting | Initiation date: Jan 2021 --> Apr 2021
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer. (Pubmed Central) - Mar 9, 2021
The common grades 1-2 adverse events were fatigue 10/22 (45.5%), decreased appetite 9/22 (40.9%), hypertension 10/22 (45.5%); the common grades 3-4 adverse events were hypertension 2/22 (9.1%) and mouth ulceration 2/22 (9.1%). Anlotinib combined with PD-1 mAb showed promising efficacy in third-line or further-line treatment of NSCLC, and its adverse effects is tolerable.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal: Clinical efficacy of anlotinib plus S-1 as a second-line therapy for recurrent or metastatic esophageal squamous cell carcinoma (Pubmed Central) - Mar 3, 2021
The adverse effects in the patients included mainly fatigue, hypertension and hand-foot syndrome, mostly of grade 1 to 2. Patients with recurrent or metastatic esophageal squamous cell carcinoma can benefit from a second-line anlotinib plus S-1 treatment, which has relatively mild adverse effects with a good safety profile.
- | Tevimbra (tislelizumab) / BeiGene, Novartis, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer (clinicaltrials.gov) - Mar 1, 2021
P2, N=40, Recruiting, Sponsor: Peking University
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial initiation date: ALT-SCLC-02: Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov) - Feb 26, 2021
P=N/A, N=80, Recruiting, Sponsor: Third Military Medical University
Patients with recurrent or metastatic esophageal squamous cell carcinoma can benefit from a second-line anlotinib plus S-1 treatment, which has relatively mild adverse effects with a good safety profile. Initiation date: Jun 2020 --> Oct 2018
- | Tagrisso (osimertinib) / AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P1/2 trial, Metastases: AUTOMAN: Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib (clinicaltrials.gov) - Feb 25, 2021
P1/2, N=25, Recruiting, Sponsor: Shanghai Chest Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial, Metastases: Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer (clinicaltrials.gov) - Feb 24, 2021
P=N/A, N=53, Not yet recruiting, Sponsor: Zhongnan Hospital
- Avastin (bevacizumab) / Roche, Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib plus carboplatin/pemetrexed in treatment-naïve advanced non-squamous NSCLC: An open-label, randomized, phase II study (ePoster Display) - Feb 24, 2021 - Abstract #ELCC2021ELCC_405;
P2
Secondary endpoints include OS, ORR, DCR, quality of life and safety profile. Clinical trial information: NCT04453423.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Safety and efficacy of anlotinib plus docetaxel in advanced non-small cell lung cancer patients after failure of first-line chemotherapy: Recent results from the ongoing phase II study (ALTER-L024) (ePoster Display) - Feb 24, 2021 - Abstract #ELCC2021ELCC_389;
P2
The most common Grade 3 adverse events (AEs) were hand-foot syndrome (13.6%), myelosuppression (4.5%) and constipation (4.5%), and no Grade4/5 observation. There were no unexpected treatment-related AEs (TRAES).Conclusions This recent analysis of the ALTER-L024 study demonstrates the encouraging clinical benefit and manageable safety profile of anlotinib plus docetaxel in patients who progressed on previous chemotherapy.Clinical trial identificationNCT03732001
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib as treatment for advanced non-small cell lung cancer: A systematic review and meta-analysis on overall survival and progression free survival (ePoster Display) - Feb 24, 2021 - Abstract #ELCC2021ELCC_387;
One study also presented better PFS and OS in refractory advanced NSCLC patients treated with anlotinib compared to the placebo group.Conclusions Anlotinib is proven to be beneficial compared to placebo in treating advanced NSCLC patients as it shows significant improvement in overall survival and also better progression free survival. Studies also found that anlotinib possess remarkable efficacy and manageable safety profile, therefore should always be considered as candidate for treatment in advanced NSCLC
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] First-line anlotinib-based combination treatment for patients with advanced non-small cell lung cancer: A threearm, prospective study (ePoster Display) - Feb 24, 2021 - Abstract #ELCC2021ELCC_381;
P1, P2
For EGFR-mutated positive patients, anlotinib plus erlotinib shows good efficacy and tolerability. For EGFR-mutated negative patients, anlotinib combines with chemotherapy or sintilimab also may be a promising first-line treatment.Clinical trial identificationNCT03628521
- Avastin (bevacizumab) / Roche, Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] A phase I study of TQ-B2450, a PD-L1 mAb, plus anlotinib in EGFR+ advanced NSCLC patients failed to prior EGFR TKI therapies (ePoster Display) - Feb 24, 2021 - Abstract #ELCC2021ELCC_365;
Based on dose exploration, 12 mg is the RP2D. Further evaluation is warranted for pts with EGFR+ advanced NSCLC who failed to prior EGFR TKI therapies.Clinical trial identificationChiCTR1900026273
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Synergistic inhibition of growth of KRAS-driven NSCLC by MEK inhibitor in combination with a novel multi-target tyrosine kinase inhibitor anlotinib via IGFBP-mediated signaling (ePoster Display) - Feb 24, 2021 - Abstract #ELCC2021ELCC_244;
Furthermore, we reported that the expression of IGFBP2 decreased significantly in the dual-drug group, which was a key protein that mediated the synergistic effect by regulating the cell cycle and EMT process. Recombinant IGFBP2 protein could restore the inhibitory effects of dual drugs on KRAS-mutant tumor proliferation, invasion and migration.Conclusions Overall, the findings of this research provide insights for clinical application of anlotinib and trametinib in treating KRAS-driven NSCLC
- | Imfinzi (durvalumab) / AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial initiation date: Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer (clinicaltrials.gov) - Feb 20, 2021
P2, N=120, Not yet recruiting, Sponsor: Henan Cancer Hospital
Recombinant IGFBP2 protein could restore the inhibitory effects of dual drugs on KRAS-mutant tumor proliferation, invasion and migration.Conclusions Overall, the findings of this research provide insights for clinical application of anlotinib and trametinib in treating KRAS-driven NSCLC Initiation date: Dec 2020 --> Apr 2021
- | Imfinzi (durvalumab) / AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study (clinicaltrials.gov) - Feb 20, 2021
P2, N=39, Recruiting, Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 20, 2021
P2, N=45, Recruiting, Sponsor: Yong Chen
- | Focus V (anlotinib) / Advenchen, Sino Biopharm, Zejula (niraparib) / GSK, J&J, Takeda
New P1 trial, Metastases: Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors (clinicaltrials.gov) - Feb 20, 2021
P1, N=52, Not yet recruiting, Sponsor: Beijing Cancer Hospital
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal: Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil porassium capsules) + oxaliplatin) in treating stage IV gastric cancer: study protocol for a single-armed and single-centred clinical trial. (Pubmed Central) - Feb 20, 2021
The results of this study will be disseminated at several research conferences and as published articles in peer-reviewed journals. ChiCTR1900026291 (registration date: 29 September 2019).
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal: Gastrointestinal hemorrhage caused by duodenal metastasis from a primary lung adenocarcinoma: A case report. (Pubmed Central) - Feb 20, 2021
Prior to the second cycle of targeted treatment with anlotinib, the patient reported severe hematochezia...However, when treating patients with lung cancer presenting with digestive symptoms or other distant metastatic sites, clinicians should consider the possibility of gastrointestinal metastasis so that it can be identified in a timely manner. If lesions exist, doctors should locate these and perform biopsies to conduct histopathological and immunohistochemical examinations to make a clear diagnosis.
- | Tyvyt (sintilimab) / Eli Lilly, AiTan (rivoceranib) / HLB Bio Group
Enrollment change, IO biomarker: Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer (clinicaltrials.gov) - Feb 19, 2021
P2, N=34, Recruiting, Sponsor: Jiuda Zhao
If lesions exist, doctors should locate these and perform biopsies to conduct histopathological and immunohistochemical examinations to make a clear diagnosis. N=26 --> 34
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: HZCH-2019-004: A Single-arm, Phase ? Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer (clinicaltrials.gov) - Feb 16, 2021
P2, N=40, Recruiting, Sponsor: First People's Hospital of Hangzhou
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal: Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas. (Pubmed Central) - Feb 13, 2021
This study shows that anlotinib combined with liposomal doxorubicin followed by anlotinib maintenance is effective in patients with metastatic STS, and most AEs of this combined therapy are mild and acceptable. Further investigation on its efficacy is warranted.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, Metastases: A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy (clinicaltrials.gov) - Feb 10, 2021
P2, N=42, Not yet recruiting, Sponsor: Chinese Academy of Medical Sciences
- |||| Anniko (penpulimab) / Akesobio, Sino Biopharm
New P2 trial, Combination therapy, Metastases: A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov) - Feb 3, 2021
P2, N=90, Recruiting, Sponsor: Akeso
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial: ALT-SCLC-02: Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov) - Feb 1, 2021
P=N/A, N=80, Recruiting, Sponsor: Third Military Medical University
- Focus V (anlotinib) / Advenchen, Sino Biopharm, Lynparza (olaparib) / Merck (MSD), AstraZeneca
[VIRTUAL] ANLOLA: A single-arm, single-center, exploratory phase II trial of anlotinib combined with dose-reduced olaparib as maintenance treatment in patients with platinum-sensitive recurrent ovarian cancer () - Jan 29, 2021 - Abstract #SGO2021SGO_690;
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancerï¼A prospective open-label, single-arm, phase II clinical trial () - Jan 29, 2021 - Abstract #SGO2021SGO_597;
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib combined with pemetrexed as a further treatment of patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study () - Jan 29, 2021 - Abstract #SGO2021SGO_596;
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer：A prospective open-label, single-arm, phase II clinical trial () - Jan 29, 2021 - Abstract #SGO2021SGO_592;
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib combined with pemetrexed as a further treatment of patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study () - Jan 29, 2021 - Abstract #SGO2021SGO_574;
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] A phase II study of sintilimab plus anlotinib for Chinese patients (pts) with persistent, recurrent or metastatic cervical cancer (CC) () - Jan 29, 2021 - Abstract #SGO2021SGO_524;
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib plus chemotherapy as first-line treatment for advanced ovarian cancer: A prospective, single-arm, single-center, phase II clinical study () - Jan 29, 2021 - Abstract #SGO2021SGO_264;
- Focus V (anlotinib) / Advenchen, Sino Biopharm, Zejula (niraparib) / GSK, ZAI Lab, J&J, Takeda
[VIRTUAL] Preliminary results of anlotinib and niraparib dual therapy evaluation in platinum-resistant recurrent ovarian cancer (ANNIE): A multicenter, single-arm, phase II trial () - Jan 29, 2021 - Abstract #SGO2021SGO_263;
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date, Metastases: Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma (clinicaltrials.gov) - Jan 29, 2021
P2, N=20, Recruiting, Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Further investigation on its efficacy is warranted. Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Jul 2021
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P1 trial, Combination therapy, Metastases: Combination Therapy for First Line Treatment of Advanced Cervical Cancer (clinicaltrials.gov) - Jan 28, 2021
P1, N=20, Recruiting, Sponsor: Ruijin Hospital
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical: #WCLC20 RR to pt/etoposide + anlotinib was high (89%). mPFS 9.41 and mOS 13.87 look pretty good - but without a comparator, what conclusions can we make? We do learn about safety but I think we need fewer single arm #SCLC studies. Still, congrats and thanks to authors. #LCSM (Twitter) - Jan 28, 2021
- |||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, P2 data: #WCLC20 Poster: single arm phase II of 1L platinum + etoposide + anlotinib with anlotinib maintenance. Primary endpoint PFS + RR. Not sure that RR is a meaningful endpoint in the 1L setting given high RR with chemo alone and not a good OS surrogate... @OncoAlert #LCSM @IASLC (Twitter) - Jan 28, 2021
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data: #WCLC20 Poster: retrospective analysis of 3L anlotinib vs plat. chemo for #SCLC. Retrospective comparisons extremely challenging to do well. While numerically, anlotinib seems better, both are quite poor. Would have been good to account for platinum-sensitivity. We can do better. (Twitter) - Jan 28, 2021
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, P2 data: #WCLC20 Poster: single arm phase II study of maintenance oral anlotinib + etoposide in #SCLC. Well tolerated; mPFS of 8.7m seems promising. But just impossible to make any conclusions from a single arm maintenance study (survival bias etc). Nice work - just needs a comparator arm (Twitter) - Jan 28, 2021
- | Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm, Oncaspar liquid (pegaspargase) / Servier
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma (clinicaltrials.gov) - Jan 28, 2021
P2, N=37, Recruiting, Sponsor: Rong Tao
Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Jul 2021 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
- | Elunate (fruquintinib) - Chi / Med, Focus V (anlotinib) / Advenchen, Sino Biopharm, Stivarga (regorafenib) / Bayer
Journal: Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib. (Pubmed Central) - Jan 26, 2021
For mCRC, anlotinib as a third-line treatment is better than chemotherapy and similar to regorafenib or fruquintinib. The associated adverse reactions are tolerable.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal: Multidisciplinary diagnosis and treatment of recurrent follicular dendritic cell sarcoma in abdomen: A case report. (Pubmed Central) - Jan 26, 2021
The diagnosis and management of PNP with FDCS require close cooperation among surgeons, dermatologists, hematologists, otolaryngologists, oncologists, radiologists, pathologists, and respiratory doctors. The interesting clinical manifestations of this patient provide a multifaceted approach to the investigation of the interactions among FDCS, Castleman disease, and PNP.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma (clinicaltrials.gov) - Jan 26, 2021
P2, N=33, Recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
- | Tyvyt (sintilimab) / Eli Lilly, AiTan (rivoceranib) / HLB Bio Group
New P2 trial, IO biomarker: Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer (clinicaltrials.gov) - Jan 25, 2021
P2, N=26, Recruiting, Sponsor: Jiuda Zhao
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: ATNPC: Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jan 21, 2021
P2, N=53, Not yet recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer (clinicaltrials.gov) - Jan 21, 2021
P2, N=30, Recruiting, Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Clinical data, Journal: Radiological, histopathological findings, and clinical outcome of pulmonary artery sarcoma. (Pubmed Central) - Jan 20, 2021
Nine patients received chemotherapy; and three of them received targeted therapy with anlotinib after chemotherapy...In conclusion, the most appropriate approach to get tissue specimen needs to be tailored to every pulmonary artery sarcoma patient. Pulmonary endarterectomy combined with chemotherapy and targeted therapy has prolonged their survival time.
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: Toripalimab Combined With Anlotinib for Patients With Advanced, Relapsed, or Refractory Gastric, or Esophagogastric Junction Cancer (EGJC) (clinicaltrials.gov) - Jan 18, 2021
P2, N=62, Recruiting, Sponsor: The Affiliated Hospital of Qingdao University
- |||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, P3 data: #GI21 @ASCO #Highlights The #efficacy and #safety of #anlotinib in refractory #colorectalCancer: A double-blinded, placebo controlled, randomized phase III #ALTER0703 trial @ASCO_pubs @NicoleKuderer @DevikaDasMD @KatsuakiMaehara @GIcancerDoc @isteaus @ShaalanBeg @dokter_onkologi (Twitter) - Jan 16, 2021
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal: Treatment of adenoid cystic carcinoma of sphenoid sinus with lung metastasis by arotinib: a case report (Pubmed Central) - Jan 12, 2021
Pulmonary endarterectomy combined with chemotherapy and targeted therapy has prolonged their survival time. No abstract available